Between 2012 and 2016, there were an estimated 34,800 annual cases of HPV-related cancer in the United States, 92% of which were attributed to strains of the virus covered by the 9-valent HPV vaccine.
In 2018, adolescent vaccination coverage in the United States continued to improve for meningococcal and HPV vaccines and remains high for tetanus and reduced diphtheria toxoids and acellular pertussis vaccine.
Oral HPV prevalence has decreased in unvaccinated men, possibly because of herd protection but has remained unchanged in unvaccinated women from 2009 to 2016.
Men are less knowledgeable than women about human papillomavirus (HPV), HPV vaccination, and the correlation between HPV and cancer.
There are areas for improvement for pediatricians and family physicians in recommendation and delivery methods for the human papillomavirus vaccine.
Ninety-two percent of HPV-related cancers are attributable to HPV types targeted by the 9-valent HPV vaccine.
Coverage with the HPV vaccine increased among boys from 2017 to 2018.
Catch-up HPV vaccinations are recommended for all persons through age 26 years and should be considered for some persons aged 27 to 45 years.
Since vaccines against HPV were made available in Europe in 2006, they have been highly effective in preventing infection and disease by the vaccine types.
The CDC ACIP has voted to expand routine and catch-up HPV vaccination in males through 26 years of age who are inadequately vaccinated.
